Today: 9 June 2026
AMD stock price slips after early pop as OpenAI chip hunt meets earnings day
3 February 2026
2 mins read

AMD stock price slips after early pop as OpenAI chip hunt meets earnings day

New York, Feb 3, 2026, 10:45 (EST) — Regular session underway.

  • AMD shares slipped roughly 1.1% following an early rally, ahead of earnings due after the close
  • A Reuters report on OpenAI’s hunt for alternatives to certain Nvidia chips centered on AI “inference” demand
  • Traders await updates on data-center expansion and the AI accelerator plans

Advanced Micro Devices shares slipped 1.1% to $243.50 late this morning, after starting the day at $251 and hitting an intraday high of $252.52. The stock was down $2.77 from Monday’s close, with a low of $241.94 during the session.

The decision came after a Reuters report Monday said OpenAI is dissatisfied with the inference capabilities of certain new NVIDIA AI chips and has looked into alternatives like AMD. Inference refers to when a trained AI model produces responses, a task that may benefit from chip designs distinct from those used for training large models.

AMD faces a tricky but potentially advantageous moment. The company will release its quarterly results after Tuesday’s close, and investors have been quick to pick up on any indication that major AI customers are expanding their supplier base beyond Nvidia.

Analysts forecast AMD will post adjusted earnings near $1.32 per share on about $9.6 billion in revenue for the December quarter, Bloomberg consensus shows, as cited by Yahoo Finance. The report also highlighted rising investor caution around whether Big Tech’s AI investments are delivering immediate gains for chipmakers.

RBC Capital Markets analyst Srini Pajjuri held a “Sector Perform” rating and maintained a $230 target but flagged expectations for a “beat and raise” fueled by server demand and market-share gains. He also highlighted execution risks tied to rack-scale systems and supply constraints. Additionally, Pajjuri warned that custom in-house chips — ASICs, or application-specific integrated circuits — could narrow the competitive landscape by 2026-27. Investing.com

HSBC analyst Frank Lee bumped his price target up to $335 from $300 while maintaining a Buy rating, according to Barron’s. He linked the outlook to “agentic AI” — software that plans and acts with minimal human input — which could boost server CPU demand.

The OpenAI report shook up the sector unevenly. Nvidia shares fell roughly 3.1% on Tuesday, whereas Intel climbed around 2.3%.

Investors are keen to hear details on data-center revenue and AI accelerator supply, along with whether AMD can expand demand past a few key marquee clients. Updates on the timing of new accelerators and rack-scale products will draw close scrutiny, especially after recent turbulence in the AI hardware sector.

The scene remains unsettled, even for an earnings week. Reuters noted that certain U.S. labor data releases are delayed due to a partial government shutdown, injecting fresh uncertainty into rate and growth forecasts amid corporate reports.

The downside is clear: expectations are sky-high, and a cautious outlook could snuff out the OpenAI buzz fast. Traders also fret that strong demand might hit supply bottlenecks, or that pricing pressure will ramp up as customers haggle for cheaper inference compute.

AMD will release its earnings after the market closes and hold a conference call at 5:00 p.m. EST. The focus will be on guidance for the March quarter and any fresh details on its AI strategy. CTO Mark Papermaster is also lined up to speak at a Morgan Stanley tech conference on March 3.

Stock Market Today

  • U.S. Inflation Poised to Exceed 4% for First Time Since 2023, Pressures Mount on Fed
    June 9, 2026, 10:06 AM EDT. U.S. inflation is set to surpass 4% for the first time since 2023, signaling rising consumer prices and intensifying economic pressures. This uptick, measured by the year-over-year increase in the Consumer Price Index (CPI), highlights renewed challenges for the Federal Reserve (Fed) as it grapples with balancing inflation control against economic growth. The rise in inflation may influence the Fed's monetary policy decisions amid concerns over sustained price increases impacting households and businesses for the remainder of the year.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Constellation Software’s 48% slide has investors split as AI fears rattle software stocks
Previous Story

Constellation Software’s 48% slide has investors split as AI fears rattle software stocks

SCHD dividend ETF is beating the S&P 500 in 2026 — what’s driving the comeback
Next Story

SCHD dividend ETF is beating the S&P 500 in 2026 — what’s driving the comeback

Go toTop